ConductScience.org, home

Paper563233

Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine.

Brockman RW and 2 others. Biochem Pharmacol, 1977. Cited by 132 papers, by iCite.

Cite this record

ConductScience Library. Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine. Papers, record 563233. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/563233

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine.
PubMed
Journal
Biochem Pharmacol
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
132
iCite
Relative citation ratio, by iCite
4.35
iCite
Revised in PubMed
2019-06-23
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brockman RWR W
2Schabel FM JrF M
3Montgomery JAJ A

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
VidarabineMajor topic
Animals
Cells, Cultured
DNA, Neoplasm
Leukemia L1210
Mice
Time Factors

Source PubMed

Download CSV of topics

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.

PMIDTitleJournalYearIn PapersSource
42239518Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism.Front Pharmacol2026https://conductscience.org/library/papers/42239518PubMed
41709524Physiologically Based Pharmacokinetic Virtual Twin Approach for Fludarabine Dosing in Pediatric Hematopoietic Stem Cell Transplantation.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/41709524PubMed
38856835Anticancer potential and structure activity studies of purine and pyrimidine derivatives: an updated review.Mol Divers2025https://conductscience.org/library/papers/38856835PubMed
33925713Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71.Viruses2021https://conductscience.org/library/papers/33925713PubMed
28624910Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?J Cancer Res Clin Oncol2017https://conductscience.org/library/papers/28624910PubMed
28108896Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.Mol Divers2017https://conductscience.org/library/papers/28108896PubMed
24066967New insights into the synergism of nucleoside analogs with radiotherapy.Radiat Oncol2013https://conductscience.org/library/papers/24066967PubMed
21422739Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.Proc Jpn Acad Ser B Phys Biol Sci2011https://conductscience.org/library/papers/21422739PubMed
19436622Fludarabine in the treatment of chronic lymphocytic leukemia: a review.Ther Clin Risk Manag2009https://conductscience.org/library/papers/19436622PubMed
14576856Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.Oncogene2003https://conductscience.org/library/papers/14576856PubMed
11888330Cellular and clinical pharmacology of fludarabine.Clin Pharmacokinet2002https://conductscience.org/library/papers/11888330PubMed
11417472Nucleoside analogues: mechanisms of drug resistance and reversal strategies.Leukemia2001https://conductscience.org/library/papers/11417472PubMed
9179529Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.Drugs1997https://conductscience.org/library/papers/9179529PubMed
7686467Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.Drugs1993https://conductscience.org/library/papers/7686467PubMed
7532163Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.Invest New Drugs1994https://conductscience.org/library/papers/7532163PubMed
7525187Evolution of the arabinosides and the pharmacology of fludarabine.Drugs1994https://conductscience.org/library/papers/7525187PubMed
3327628Membrane transport and the antineoplastic action of nucleoside analogues.Cancer Metastasis Rev1987https://conductscience.org/library/papers/3327628PubMed
2456162Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/2456162PubMed
24318039-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/2431803PubMed
2427240Pharmacokinetic study of fludarabine phosphate (NSC 312887).Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/2427240PubMed

See all 26 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/563233

GET https://conductscience.org/api/papers/v1/563233/cited_by?page=2